8/19/22

Kymera Announces $150 Million Private Placement Equity Financing

WATERTOWN, Mass., Aug. 19, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, has entered into a securities purchase agreement with certain